Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen open-label phase 3 trial in neovascular age-related macular degeneration
2005-004514-32Phase 3Terminated
- Start
- Dec 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegaptanib sodium in exudative macular degeneration. Primary endpoint: Mean change in distance visual acuity from baseline to week 54. Started Dec 2005; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2005-004514-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004514-32.